Exelixis (LTS:0IJO) Total Liabilities : $676 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exelixis Total Liabilities?

Exelixis's Total Liabilities for the quarter that ended in Mar. 2024 was $676 Mil.

Exelixis's quarterly Total Liabilities increased from Sep. 2023 ($629.29 Mil) to Dec. 2023 ($678.45 Mil) but then declined from Dec. 2023 ($678.45 Mil) to Mar. 2024 ($675.74 Mil).

Exelixis's annual Total Liabilities increased from Dec. 2021 ($405.62 Mil) to Dec. 2022 ($583.06 Mil) and increased from Dec. 2022 ($583.06 Mil) to Dec. 2023 ($678.45 Mil).

Exelixis Total Liabilities Historical Data

The historical data trend for Exelixis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Total Liabilities Chart

Exelixis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

199.70

258.22

405.62

583.06

678.45

Exelixis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															588.22	614.53	629.29	678.45	675.74

Exelixis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Exelixis's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	394.277	+	(189.944	+	94.224
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	678

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2942.357	-	2263.912
	=	678

Exelixis's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	373.01	+	(201.466	+	101.268
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	676

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2803.752	-	2128.008
	=	676

Exelixis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Exelixis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (LTS:0IJO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EXEL:USA EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (LTS:0IJO) Headlines

No Headlines